Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does RISPERIDONE Cause Neuroleptic malignant syndrome? 1,258 Reports in FDA Database

Sharpen Your Memory & Focus Naturally

NeuroZoom — 35 clinically studied ingredients. No stimulants. Pure brain support.

Boost Your Brain

According to the FDA Adverse Event Reporting System (FAERS), 1,258 reports of Neuroleptic malignant syndrome have been filed in association with RISPERIDONE (Risperidone). This represents 1.6% of all adverse event reports for RISPERIDONE.

1,258
Reports of Neuroleptic malignant syndrome with RISPERIDONE
1.6%
of all RISPERIDONE reports
151
Deaths
947
Hospitalizations

How Dangerous Is Neuroleptic malignant syndrome From RISPERIDONE?

Of the 1,258 reports, 151 (12.0%) resulted in death, 947 (75.3%) required hospitalization, and 363 (28.9%) were considered life-threatening.

Is Neuroleptic malignant syndrome Listed in the Official Label?

Yes, Neuroleptic malignant syndrome is listed as a known adverse reaction in the official FDA drug label for RISPERIDONE.

What Other Side Effects Does RISPERIDONE Cause?

Gynaecomastia (24,453) Off label use (10,376) Abnormal weight gain (9,418) Weight increased (6,885) Emotional disorder (5,809) Product use in unapproved indication (5,551) Drug ineffective (5,232) Injury (4,447) Hyperprolactinaemia (4,124) Galactorrhoea (3,513)

What Other Drugs Cause Neuroleptic malignant syndrome?

QUETIAPINE (1,756) OLANZAPINE (1,748) HALOPERIDOL (1,244) ARIPIPRAZOLE (1,138) CLOZAPINE (899) LITHIUM (506) LORAZEPAM (437) PALIPERIDONE (355) VALPROIC ACID (352) SERTRALINE (309)

Which RISPERIDONE Alternatives Have Lower Neuroleptic malignant syndrome Risk?

RISPERIDONE vs RITALIN RISPERIDONE vs RITLECITINIB RISPERIDONE vs RITODRINE RISPERIDONE vs RITONAVIR RISPERIDONE vs RITUXAN

Related Pages

RISPERIDONE Full Profile All Neuroleptic malignant syndrome Reports All Drugs Causing Neuroleptic malignant syndrome RISPERIDONE Demographics